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Background/Aims: Alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP) have been used as
diagnostic tools for hepatocellular carcinoma (HCC). However, prediction of outcome using AFP and DCP has not
been elucidated. We investigated the clinical role of AFP and DCP as predictors of treatment outcome in patients
with HCC undergoing trans-arterial chemoembolization (TACE).
Methods: Between January 2003 and December 2005, we enrolled 115 treatment-naïve patients who received
TACE as an initial treatment modality. An AFP or DCP response was defined as a reduction of more than 50% from
the baseline level 1 month after TACE. Patients with AFP < 20 ng/mL or DCP < 20 mAU/mL were excluded.
Results: The median age was 59 years and the male gender predominated (n = 81, 70.4%). AFP and DCP response
was identified in 91 (79.1%) and 77 (66.9%) patients after TACE. Although progression-free survival (PFS) did not
differ according to AFP response (P = 0.150), AFP responders showed significantly better overall survival (OS) than
non-responders (34.9 vs. 13.2 months; P = 0.002). In contrast, DCP response did not influence either PFS or OS (all
P > 0.05). Multivariate analyses showed that gamma-glutamyltranspeptidase and baseline AFP were predictors of
PFS (all P < 0.05) and that male gender, the presence of liver cirrhosis, baseline DCP, number of measurable tumors
and AFP response were independent predictors of OS (all P < 0.05).
Conclusions: AFP response and higher baseline DCP level are significant predictors of OS in treatment-naïve
patients with HCC receiving TACE who showed pretreatment elevation of both AFP and DCP.
Keywords: Alpha-fetoprotein, Des gamma carboxy prothrombin, Transarterial chemoembolization, Tumor marker
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Hepatocellular carcinoma (HCC) is the third most com-
mon cause of cancer-related death globally [1]. Unless
HCC is diagnosed at an early stage when liver trans-
plantation, hepatic resection, and radiofrequency abla-
tion are feasible, a poor prognosis is expected due to the* Correspondence: DRPJY@yuhs.ac
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reproduction in any medium, provided the orlimited treatment options [2]. Although several treatment
modalities have been applied to advanced HCC, [3,4] only
trans-arterial chemoembolization (TACE) [5-10] and Sor-
afenib [11] exhibit survival benefit. Accordingly, TACE
and Sorafenib are recommended for HCC in the inter-
mediate and advanced Barcelona Clinic of Liver Cancer
(BCLC) stages, respectively [12,13].
Alpha-fetoprotein (AFP) was first described about
40 years ago and is proposed as a screening and diagnostic
tool for HCC [14-19]. Recently, the national comprehensive
cancer network guidelines also proposed AFP as a alterna-
tive tool for diagnosing HCC [20]. Though there is no. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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AFP cut-offs [21,22]. Moreover, several studies have
reported that changes in AFP levels may predict treatment
outcome [23-25]. A recent study showed a correlation
between AFP response and radiologic response, time-to-
progression (TTP), progression-free survival (PFS), and
overall survival (OS) in patients treated with loco-regional
therapies [26,27]. In contrast, controversies regarding the
diagnostic role of des gamma carboxy prothrombin (DCP)
remain. However, the clinical significance of DCP is empha-
sized in Asia [28]. Recently, its clinical usefulness was
emphasized in a different ethnic group [17,29,30].
The primary aim of this study was to determine the
clinical utility of AFP and DCP as predictors of treatment
outcome in patients with HCC undergoing TACE.
Patients and methods
Patients
Between January 2003 and December 2005, a total of
270 patients underwent TACE as an initial treatment
modality at Severance Hospital, Yonsei University College
of Medicine, Seoul, Korea. Of these, we excluded 104 with
an AFP level < 20 ng/mL [31] or DCP level < 20 mAU/mL,
47 without baseline or follow-up tumor markers, and four
with curative resection after TACE. Finally, a total of 115
patients were recruited for statistical analysis and
followed-up until December, 2009. The study protocol
was approved by the independent institutional review
board of our institute.
Diagnosis of HCC
HCC was diagnosed based on the guidelines of American
Association for the Study of Liver Diseases [32]. Briefly,
patients were diagnosed with HCC if they had a tumor
with a maximum diameter >2 cm, typical features of HCC
on dynamic computed tomography (CT) (defined as
hyperattenuation in the arterial phase and early washout
in the portal phase), and an AFP >200 ng/ml [32]. If the
maximum diameter of tumor was 1–2 cm, dynamic CT
and magnetic resonance imaging (MRI) were performed.
HCC was diagnosed if coincidental typical features of
HCC were noted. If the tumor did not satisfy the above
criteria, a biopsy was performed. When the tumor was
<1 cm, ultrasonography was repeated after 3 months.
Treatment and response-evaluation protocols
After diagnosis of HCC was confirmed, angiography was
performed to identify the major arterial supply to HCC.
TACE was conducted using a solution of 20–50 mg doxo-
rubicin hydrochloride in a 5–20 ml mixed solution of
lipiodol and contrast agent. Subsequently, embolization
was performed using gelatin sponge particles after TACE.
After TACE, occlusion of target vessels and absence of
additional tumor blood supply was confirmed.Radiological response evaluation using CT or MRI and
tumor marker response were evaluated 3–4 weeks after
TACE. If viable tumor remained at CT or MRI, TACE was
repeated. After 2–3 consecutive TACE sessions, at the time
of best radiologic response, radiological and tumor marker
responses were evaluated. If compact lipiodolization was
noted and no viable HCC was identified, than radiologic
evaluation and tumor marker measurement were done
within 3 months to assess HCC recurrence. If progressive
disease was identified, other treatment modalities were
considered.
Tumor marker response evaluation
Baseline AFP and DCP levels were determined before
TACE. Follow up tumor marker were checked every 3 ~
4 weeks after TACE concurrent with CT or MRI. To
analyze tumor marker response, we determined AFP and
DCP levels when the best radiologic response was reached
after 2–3 consecutive sessions of TACE. Tumor marker
response evaluation was performed when complete remis-
sion is observed after consecutive session of TACE in most
of subjects, but tumor marker response also analyzed
within subject who did not get complete remission. In
these patients, tumor marker checked just before last
TACE concluded as progressive diseases by mRECIST
criteria was used. AFP/DCP levels were measured
using a microparticle enzyme immunoassay (AFP, Bayer,
Leverkusen, Germany; DCP, Sanko Junyaku Co., Tokyo,
Japan). AFP response was defined as a reduction in AFP
level of more than 50% from baseline, according to a pre-
vious study [27]. Similarly, DCP response was defined as a
reduction in DCP level of more than 50% from baseline.
Radiologic response evaluation
Radiologic tumor response was evaluated using the
WHO and modified RECIST criteria by CT or MRI. For
the WHO criteria, minimum cross product was com-
pared to baseline cross product for calculating change in
size. Complete response (CR) was defined as complete
disappearance; partial response (PR) was defined as 50%
decrease; progressive disease (PD) was defined as a more
than 25% increase in the cross product from maximum
decrease. All other findings were defined as stable disease
(SD). In the mRECIST criteria, length of the major axis of
a viable tumor was compared to baseline for calculating
change in size. CR was taken as the absence of any enhan-
cing tissue, PR as a 30% decrease in enhancing tissue, and
SD as a less than 20% decrease.
Calculation of progression-free and overall survival
The progression-free survival (PFS) time is defined as the
time from the TACE start date to the first observation of
tumor progression confirmed by mRECIST criteria or
death due to any cause. To account for the fact that some
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gression, PFS for these patients was censored at the time
of last follow-up. The overall survival (OS) was calculated
from the time of study entry to death. If the patient had
no recorded date of death or was still alive at the time of
the analysis, OS for these patients was censored at the
date that the patient was last seen alive.
Statistical analysis
An independent t-test or Mann–Whitney U test was
used to compare continuous variables, and a chi-square
or Fisher’s exact test was used to compare categorical
variables between two groups (AFP responder vs. AFP
non-responder and DCP responder vs. DCP non-re-
sponder). AFP and DCP response together with conven-
tional clinical variables at the time of entry to the study
were used to identify independent factors that influence
PFS and OS via the Cox proportional hazards model.
Hazard ratio (HR) and the corresponding 95% confi-
dence intervals (CI) were also indicated. Age, sex,
etiology, anti-viral therapy, HBV-DNA positivity, Child
Pugh classification, liver cirrhosis, GGT, baseline AFP
and DCP, AFP response, DCP responce, BCLC stage,
number of tumor, size of tumor, WHO response and
mRECIST response were included in univariate regres-
sion test on PFS and OS. Gender, Child-Pugh Classifica-
tion, GGT, AFP, DCP, number and size of tumor, BCLC
stage were included in multivariate regression test on PFS.
Gender, Cirrhosis, GGT, AFP response, Baseline DCP,
number and size of tumor were included on OS analysis.
PFS and OS were calculated using the Kaplan–Meier
method and compared using a log rank test. Statistical
analyses were performed using SPSS ver. 11.0 software
(SPSS Inc., Chicago, Ill).
Results
Baseline characteristics
Baseline characteristics of the 115 patients are described
in Table 1. The median age was 59 years and male gen-
der predominated (n = 81, 70.4%). Hepatitis B virus was
the most common etiology of HCC (n = 80, 69.6%). The
median baseline AFP and DCP were 296.7 ng/mL and
231 mAU/mL, respectively. Median follow up was 26
(range, 1.2–75.9) months.
Tumor marker responses
After TACE, 91 (79.1%) patients showed AFP response
and 24 (20.9%) were non-responders (Table 1). Baseline
characteristics were similar between AFP responders and
non-responders, except for the significantly higher pro-
portion of Child–Pugh class A in AFP responders than
non-responders (97.8 vs. 79.2%; P = 0.004). In contrast,
77 (66.9%) patients showed a DCP response, and 38
(33.1%) did not (Table 1). DCP non-responders showeda significantly higher proportion of solitary HCC (65.8
vs. 45.4%; P = 0.048).
Objective responses after TACE and correlation with
tumor marker responses
Table 2 shows objective responses after TACE using
WHO and mRECIST criteria and their correlations with
AFP and DCP responses. Neither AFP nor DCP responses
showed a significant correlation with radiological response
evaluated using the WHO criteria. In contrast, AFP,
but not DCP, response was significantly correlated
with radiological response evaluated using the mRECIST
criteria (P = 0.045).
Independent predictors for PFS and OS
Univariate and multivariate analyses were used to identify
independent predictors of PFS and OS (Table 3). Regarding
PFS prediction, gamma glutamyltranspeptidase (GGT)
(HR, 1.003; 95% CI 1.001–1.004; P = 0.012) and baseline
AFP (HR 1.000; 95% CI 1.000–1.001; P = 0.049) were iden-
tified as independent predictors. Regarding OS prediction,
male gender (HR, 2.119; 95% CI, 1.040–4.320; P = 0.039),
the presence of cirrhosis (HR, 2.319; 95% CI, 1.281–4.201;
P = 0.005), baseline DCP level (HR, 1.000; 95% CI, 1.000–
1.001; P = 0.028), number of tumors(HR, 1.443; 95% CI,
1.035-2.011; P = 0.030) and AFP response (HR, 0.276;
95% CI; 0.147–0.518; P < 0.001) were independent predic-
tors of OS. The Kaplan–Meier curves of PFS and OS
according to AFP and DCP responses are indicated in
Figures 1 and 2.
DCP response within higher DCP levels
DCP response did not show statistical significance for pre-
diction of PFS or OS after TACE. However, when we ana-
lyzed a subgroup of patients with a baseline DCP level >
200 mAU/ml [31], a significant correlation between DCP
response and OS emerged (median 26.7 months in DCP
responders vs. 7.5 months in DCP non-responders; log
rank test P = 0.002). Thus, application of DCP response to
prediction of treatment response and the corresponding
optimal cutoff values of baseline DCP level to enhance the
treatment-outcome predictability of DCP response should
be further investigated.
Combined serological endpoint
Sub-analysis was done to find out whether combined
serological endpoint (AFP and/or DCP responses) would
improve it prognostication [33]. AFP and/or DCP
responders were stratified into combined tumor marker
responders (cTM responders, n = 99) whereas subjects
without AFP and DCP responses were stratified into cTM
non-responders (n =16). PFS was similar between cTM
responders and non-responders (15.1 vs. 10.5 months; log
rank test, P = 0.259) whereas OS was significantly longer in




valueAll patients AFP responder AFP non-responder DCP responder DCP non-responder
(n = 115) (n = 91, 79.1%) (n = 24, 20.9%) (n = 77, 66.9%) (n = 38, 33.1%)
Age, years 59 (37 - 78) 59 (37 - 78) 59 (39 - 75) 0.783 59 (37 - 78) 59.9 (40 - 77) 0.661
Male 81 (70.4) 63 (69.2) 18 (75.0) 0.802 53 (68.8) 28 (73.7) 0.668
Etiology
HBV/ HCV/ Others 80 (69.5)/ 18 (15.7)/ 17 (14.8) 63 (69.2)/ 15 (16.5) /13 (14.3) 17 (70.8)/ 3 (12.5)/ 4 (16.7) 0.883 53 (68.8)/ 13 (16.9)/ 11 (14.3) 27 (71.0)/ 5 (13.2)/ 6 (15.8) 0.908
Child-Pugh, A vs. B 108 (93.9)/ 7 (6.1) 89 (97.8)/ 2 (2.2) 19 (79.2)/ 5 (20.8) 0.004 74 (96.1) / 3 (3.9) 34 (89.5)/ 4(10.5) 0.217
Liver cirrhosis 72 (62.6)/ 43 (37.4) 56 (61.5)/ 35 (38.5) 16 (66.7)/ 8(33.3) 0.813 46 (59.7) / 31 (40.3) 26 (68.4)/ 12(31.6) 0.417
Biochemical Variables
Platelet, 103/uL 127 (38 - 414) 134 (38 - 332) 108 (64 - 414) 0.585 123 (38 - 332) 133.5 (60-414) 0.467
ALT, IU/L 38 (12 - 315) 39 (12 - 315) 38 (18 - 116) 0.088 39 (12 - 257) 37 (18 - 315) 0.561
Bilirubin, mg/dL 0.7 (0.2 - 13.4) 0.7 (0.2 - 3.0) 0.6 (0.3 - 13.4) 0.405 0.7 (0.2 - 3.0) 0.6 (0.2-13.4) 0.462
AFP, ng/mL 296.7 (24.23 - 83000) 320.95 (24.23 - 50000) 142.96 (26 - 83000) 0.496 320.95 (24.23 - 83000) 280.08 (25.22 - 50000) 0.774
DCP, mAU/mL 231 (20 - 2000) 231 (20 - 2000) 228.5 (23 - 2000) 0.304 276 (20 - 2000) 62.5 (20 - 2000) 0.464
Number of tumora
1/ 2/ 3/ >4 60 (52.2)/ 18 (15.7)/
9 (7.8)/ 28 (24.3)
13 (54.2)/ 5 (20.8)/
2 (8.3)/ 4 (16.7)
47 (51,6)/ 13 (14.3)/
7 (7.7)/ 24 (26.4)
0.732 35(45.4)/ 13 (16.9)/
6 (7.8)/ 23 (29.9)
25 (65,8)/ 5 (13.2)/
3(8.0)/ 5(13.2)
0.160
Size of tumor, mmb 47 (10 - 160) 47 (10 - 160) 45.5 (10 - 151) 0.531 49 (10 - 160) 36 (10 - 160) 0.473
BCLC stage
A/ B/ C 62 (53.9)/ 49 (42.6)/ 4 (3.5) 47 (51.6)/ 40 (44.0)/ 4 (4.4) 15 (62.5)/ 9 (37.5)/ 0 (0.0) 0.484 40 (51.9)/ 36 (46.8)/ 1 (1.3) 22 (57.9)/ 13 (34.2)/ 3 (7.9) 0.117
TNM stage of LCSGJ
I/ II/ III/ IVa 21 (18.3)/ 40 (34.8)/ 19 (20.9)/ 29 (31.9)/ 2 (8.3)/ 11 (45.8)/ 0.412 9 (11.7)/ 31 (40.3)/ 12 (31.6)/ 9 (23.7)/ 0.027
42 (36.5)/ 12 (10.4) 34 (37.4)/ 9 (9.9) 8 (33.3)/ 3 (1.5) 27 (35.1)/ 10 (13.0) 15 (39.5)/ 2 (5.3)
Variables are expressed as n (%) or median (range).
anumber of measurable lesion, btotal size of measurable lesion.
AFP, alpha-fetoprotein; DCP, des gamma carboxy prothrombin; HBV, hepatitis B-virus; HCV, hepatitis C-virus; ALT, alanine aminotransferase; BCLC, Barcelona Clinic Liver Cancer; TNM, Tumor-Node-Metastasis; LCSGJ,

















Table 3 Independent predictors for progression-free and overall survival
Variables Progression-free survival Overall survival
Univariate Multivariate Univariate Multivariate
P value P value HR 95% CI P value P value HR 95% CI
Age, years 0.770 - - 0.578 - -
Male 0.028 0.443 - - 0.013 0.039 2.119 1.040-4.320
Etiology
Viral vs. others 0.252 - - 0.916 - -
Anti-viral therapy 0.325 - - 0.047 0.453 - -
HBV-DNA positivity 0.165 - - 0.231 - -
HBeAg positivity 0.234 - - 0.324 - -
Child-Pugh class, A vs. B 0.040 0.832 - - 0.787 - -
Liver cirrhosis 0.101 - - 0.002 0.005 2.319 1.281-4.201
GGT 0.001 0.012 1.003 1.001-1.004 0.014 0.068 - -
Tumor marker
Baseline AFP 0.008 0.049 1.000 1.000-1.001 0.486 - -
Baseline DCP 0.039 0.686 - - 0.001 0.028 1.000 1.000-1.001
AFP response 0.155 - - 0.023 <0.001 0.276 0.147-0.518
DCP response 0.756 - - 0.205 - -
BCLC stage, A vs. ≥B 0.002 0.409 - - 0.003 0.502 - -
Number of tumora 0.001 0.373 - - <0.001 0.030 1.443 1.035-2.011
Size of Tumorb 0.021 0.927 - - <0.001 0.085 - -
WHO response
CR + PR + SD vs. PD 0.419 - - 0.945 - -
mRECIST
CR + PR + SD vs. PD 0.107 - - 0.548 - -
anumber of measurable lesion, btotal size of measurable lesion.
HR, hazard ratio; CI, confidence interval; AFP, alpha-fetoprotein; DCP, des gamma carboxy prothrombin; BCLC, Barcelona Clinic Liver Cancer.
Reference value: others, Child-Pugh class B, BCLC stage ≥ B, PD with WHO criteria, and PD with mRECIST criteria.
Table 2 Objective responses after TACE and correlation with tumor marker responses
Radiologic
response
AFP response P value DCP response P value
AFP responder AFP non-responder DCP responder DCP non-responder
(n = 91, 79.1%) (n = 24, 20.9%) (n = 77, 66.9%) (n = 38, 33.1%)
WHO criteria
0.196 0.308
Complete response 0 (0) 0 (0) 0 (0) 0 (0)
Partial response 17 (18.7) 3 (12.5) 11 (14.3) 9 (23.7)
Stable disease 71 (78.0) 18 (75.0) 63 (81.8) 26 (68.4)
Progressive disease 3 (3.3) 3 (12.5) 3 (3.9) 3 (7.9)
mRECIST criteria
Complete response 70 (76.9) 13 (54.2)
0.045
55 (71.4) 28 (73.7)
0.298
Partial response 11 (12.1) 3 (12.5) 12 (15.6) 2 (5.3)
Stable disease 3 (3.3) 3 (12.5) 4 (5.2) 2 (5.3)
Progressive disease 7 (7.7) 5 (20.8) 6 (7.8) 6 (15.7)
Variables are expressed as n (%).
AFP, alpha-fetoprotein; DCP, des gamma carboxy prothrombin; WHO, World health organization; mRECIST, modified Response Evaluation Criteria in Solid Tumor.
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Figure 1 Progression-free (PFS) and overall survival (OS) curves of AFP responder and non-responder. PFS was similar between AFP
responders and non-responders (8.0 vs. 5.5 months; log rank test, P = 0.150; (A)) whereas OS were significantly better in AFP responder than non-
responder. (34.9 vs. 13.2 months; log rank test, P = 0.020; (B)).
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log rank test, P = 0.011). In addition, cTM response was
selected as one of independent predictors of OS (HR 0.312;
95% CI 0.150-0.649; P = 0.002), together with tumor size
and cirrhosis. However, cTM response did not predict PFS
independently.Discordance between cTM response and radiologic
response
We divided the study population according to cTM and
radiological responses. Definition of cTM response
described at combined serological endpoint. Similarly,
radiologic responders were defined as patients with CR/
PR/SD and radiologic non-responders as those with PD
using the mRECIST criteria. Using these definitions,
eight (6.9%) cTM responders experienced a radiologicFigure 2 Progression-free survival (PFS) and overall survival (OS) curv
not significantly different between DCP responder and non-responder (7.8
23.2 months; log rank test, P = 0.203 for OS (B)).non-response and 12 (10.4%) cTM non-responders
experienced radiologic responses; these were categorized
as discordant.
Baseline albumin level was identified as an independent
predictor of discordance between cTM response and radio-
logic response (HR, 2.747; 95% CI, 1.266–2.963; P = 0.011).
Analysis of the discordant group (n = 20) revealed that
the PFS and OS of eight cTM responders with radio-
logic non-response was not statistically different from
that of 12 cTM non-responders with radiologic response
(5.1 vs. 5.1 months; P = 0.828 for PFS and 33.8 vs.
7.5 months; P = 0.354 for OS) [Additional file 1].Discussion
Tumor response evaluation using CT or MRI after systemic
chemotherapy or loco-regional treatment is widely used toes of DCP responder and non-responder. Both PFS and OS were
vs.7.3 months; log rank test, P = 0.755 for PFS (A) and 34.9 vs.
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tegies. However, high cost, radiation hazard, and associated
cancer risks are drawbacks to these response evaluation
modalities, [34] whereas tumor marker evaluation after
anti-cancer treatment is rapid, easier to estimate, and less
expensive. Thus, the clinical implications of tumor response
evaluation using tumor markers have been continuously
investigated [35-38].
This study also showed that AFP response can be an
independent predictor of OS in patients undergoing
TACE as the first treatment modality, whereas radiologic
response was not significant in predicting PFS and OS.
Several previous studies have also proposed the clinical
usefulness of AFP response. Riaz et al. [27] proposed
AFP response after loco-regional therapy as an ancillary
method of assessing tumor response and survival, as well
as an early objective screening tool for progression by
imaging. Furthermore, the supplementary role of AFP
response for tumor response evaluation and prediction
of better survival and extrahepatic metastasis in patients
undergoing hepatic arterial infusional chemotherapy,
localized concurrent chemoradiation therapy, and anti-
angiogenic treatment such as Sorafenib and Bevacizumab
has been proposed [26,36,37]. However, to our disap-
pointment, AFP response didn’t show its novel value
of prediction in PFS of HCC patients. It might be caused
by that all subjects did not have the same follow-up period
and timing of assessment scan, furthermore definition of
PFS might be subject to bias. So it could be a limitation
of our study.
The baseline AFP level in our study also showed statis-
tical significance for predicting PFS in a multivariate
analysis (P = 0.035). Similarly, the significance of the
prognostic role of baseline AFP level has been accepted in
previous studies and several staging systems [39,40]. In
contrast, baseline DCP level was significantly associated
with OS in our study. Several other studies investigated
the usefulness of baseline DCP level, and demonstrated
that higher baseline DCP level was significantly correlated
with poor prognosis in HBV-related HCC and with a
higher risk of recurrence after curative treatment [35,41].
Although the reasons why HCC with a higher baseline
DCP level is related to poor prognosis remain uncertain, it
may in part be due to the fact that the higher baseline
DCP level is significantly associated with the presence
of vascular invasion, intra-hepatic metastasis, tumor
size, Tumor-Node-Metastasis (TNM) stage, and a high
frequency of tumor recurrence [42].
When we consider that only viable HCC can produce
AFP and that the mRECIST criteria were developed to
evaluate the amount of viable HCC, it is not surprising
that AFP response showed a significant correlation to
tumor response evaluated by mRECIST criteria. Although
DCP is also produced by viable HCC, DCP response wasnot correlated with mRECIST response. This may be
because, in contrast to AFP, DCP can be produced in sur-
rounding non-cancer tissues after being stimulated by
HCC [42], which might have attenuated the correlation
between DCP response and radiologic tumor response by
the mRECIST criteria. This also supports our result
that DCP response was not significant for predicting
PFS or OS after TACE. Because the WHO criteria do
not consider specific situations (such as necrosis and
the viable portion of HCC) neither the AFP nor DCP
responses were correlated with radiologic response
evaluation by the WHO criteria.
We further analyzed patients showing discordant out-
comes assessed by cTM response and radiologic response,
because in this situation physicians must decide whether
to maintain the current treatment modality or change it.
Although baseline albumin level was identified as a pre-
dictor of discordance between cTM response and radio-
logic response, there was no statistical difference in OS
between cTM responders with radiologic non-response
and those with cTM non-response but radiologic response
(33.8 vs. 7.5 months; P = 0.354). Because a longer OS was
noted in patients with cTM response and radiologic non-
response in spite of the lack of statistical significance and
because the clinical significance of the cTM response
might have been attenuated due to the small discordant
sub-population, a larger study is needed to reveal the role
of cTM response in these cases. In the same context, if the
role of cTM response in discordant cases can be demon-
strated, cTM non-responders who experience radiologic
response may need to have their disease progression
monitored closely.
Interestingly, baseline GGT level was identified as an
independent prognostic factor of PFS, similar to a recent
study that proposed that GGT level is an important
prognostic factor in patients with BCLC-intermediate
HCC treated with TACE [43]. Considering that GGT
level is associated with oxidative stress and resistance
to platinum drugs [44,45], the prognostic value of
GGT levels for discriminating subgroups with diffe-
rent risks of disease progression or mortality should
be determined.
This study has limitations. First, this was a retrospective
study with a relatively small sample size. Also, some study
subjects were included in article published recently and
analyzed about prognostic value of AFP and DCP by the
same institute [46]. However, the aim of this study is clearly
different from previous one focusing on the prognostic
value of baseline AFP and DCP in all patients with
treatment-naïve HCC. In the present study, we focused on
the prognostic value of the responses of AFP and DCP by
TACE. Second, we excluded patients with low baseline
AFP or DCP levels before TACE. Our results might not
apply to patients with low baseline AFP or DCP levels.
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values of AFP and DCP response simultaneously, we ine-
vitably selected only patients with elevated AFP and DCP
in spite of a potential selection bias. Third, because AFP
can be confounded by hepatic necroinflammation, the pre-
dictability of the AFP response might have been influenced.
AFP response could be poor in patients with persistently
elevated ALT after TACE. Furthermore, patients with per-
sistently elevated ALT are reportedly associated with poor
OS due to more rapid impairment of the liver function.
Physicians should be cautious in applying baseline AFP or
AFP response to patients suffering from active hepatitis or
to those without elevated baseline AFP and DCP levels. Fi-
nally, considering that TACE was introduced as a palliative
treatment for intermediate-stage HCC, many HCC patients
with BCLC stage A in our study who were indicated for
curative treatment underwent TACE. For several reasons,
these patients decide to take TACE. Some of them refused
surgical resection and others are unable to surgical resec-
tion because of their medical condition such as old age
(>70 yrs) and poor general conditions (ECOG PS ≥ 2 and/
or cachexia). Furthermore, sub-segmental TACE using
iodized oil and a gelatin sponge remains an important
therapeutic option for patients with HCC in Japan [47].
This is not surprising, because sub-segmental TACE as a
curative treatment modality has become widely accepted
in Korea as well as in Japan.
Conclusions
The present study demonstrated the clinical importance
of AFP response and baseline DCP level for predicting
OS in treatment-naïve patients with HCC undergoing
TACE as an initial treatment modality. In the future, a
treatment algorithm incorporating tumor marker re-
sponse and radiologic response, which compensate for
each other’s drawbacks, should be established to more
accurately predict treatment outcomes after TACE.Additional file
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